Silurian Pharmaceuticals, Inc. to present at the North American Cystic Fibrosis Conference, Orlando, Florida
October 27-29, 2016
Silurian will present recent results of its drug Brevenal for the treatment of defective mucociliary clearance and the prevention of exacerbations in Cystic Fibrosis, at the NACFC, Orlando, Florida, October 27-29, 2016.
Brevenal is a promising new therapy for patients with cystic fibrosis. Low doses reverse the inhibition of airway mucociliary function caused by CFTR inhibitor 172 and human neutrophil elastase (HNE) in sheep. It also alleviates bronchoconstriction caused by HNE. This demonstrates that brevenal's activity is independent of CFTR, as well as it addresses the downstream pulmonary complications cause by HNE.